Montelukast Sodium Tablet, Chewable
FDA Label NDC 42291-622

42 label sections · Submitted to the FDA by Avkare · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Avkare for the product Montelukast Sodium (NDC 42291-622). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding warning: serious neuropsychiatric events, 1 indications and usage, 1.1 asthma, 1.2 exercise-induced bronchoconstriction (eib), 1.3 allergic rhinitis, 1.4 limitations of use, 2 dosage and administration, 2.1 asthma, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

* Please review the disclaimer below.